i-SENS, Inc. stock analysis
Want to see KR:099190 full AI Analyst Report?
i-SENS, Inc. (099190) Stock Price & Analysis
099190 Stock Chart & Stats
- Day’s Range
- KRW 12,920.00 - KRW 13,680.00
- 52-Week Range
- KRW 11,700.00 - KRW 27,600.00
- Previous Close
- KRW 13,320.00
- Volume
- N/A
- Average Volume (3M)
- 70.00K
- Market Cap
- KRW 385.33B
- Enterprise Value
- KRW 571.27B
- Total Cash (Recent Filing)
- KRW 99.02B
- Total Debt (Recent Filing)
- KRW 170.56B
- Price to Earnings (P/E)
- ―
- Beta
- 0.44
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 29, 2025
- Dividend Yield
- 0.70%
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue Growth
Accelerating revenue indicates stronger demand and expanding commercial traction across the company’s diagnostic products. If sustained, this top-line momentum can improve operating leverage, support continued investment in product development, and strengthen i-SENS’s position in diabetes management markets over the coming quarters.
Stable Gross Margin
A gross margin maintained near 39–40% suggests the core products retain meaningful economic value despite recent earnings pressure. This stability provides a foundation for recovery if revenue continues growing and management can control operating costs, because incremental sales may contribute more effectively to future profitability.
Positive Operating Cash Flow
Positive operating cash flow demonstrates that the underlying business continues to generate cash from operations even while reported profitability is weak. That internally generated liquidity helps fund routine activities and provides greater resilience than a business wholly dependent on external financing during the next several months.
Bears Say
Persistent Losses
The shift from earlier profits to losses materially weakens earnings power and makes the business more dependent on a successful operational recovery. Negative margins can reduce reinvestment capacity, limit financial flexibility, and make sustained revenue growth less valuable unless costs and operating leverage improve.
Volatile Free Cash Flow
Repeatedly negative or volatile free cash flow indicates that accounting revenue and operating cash generation are not consistently translating into discretionary cash. This raises funding and execution risk, potentially constraining investment in growth initiatives and increasing reliance on balance-sheet resources if weak profitability persists.
Convertible Financing Dilution
The convertible-bond conversion increases the share count and creates dilution for existing holders, while KRW 8.89 billion of unconverted bonds remains. Ongoing conversion capacity signals that capital structure changes may continue, potentially limiting per-share participation in any eventual earnings recovery.
099190 FAQ
What was i-SENS, Inc.’s price range in the past 12 months?
What is i-SENS, Inc.’s market cap?
When is i-SENS, Inc.’s upcoming earnings report date?
How were i-SENS, Inc.’s earnings last quarter?
Is i-SENS, Inc. overvalued?
Does i-SENS, Inc. pay dividends?
What is i-SENS, Inc.’s EPS estimate?
How many shares outstanding does i-SENS, Inc. have?
What happened to i-SENS, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of i-SENS, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
i-SENS, Inc.
i-SENS Inc is a South Korean enterprise specializing in the development and marketing of biosensor technology. The company's core product line consists of blood glucose monitoring systems, including a variety of meters, monitors, and comprehensive testing kits designed to measure blood sugar levels. These essential diagnostic tools are sold under prominent brand names like CareSens, MedTrust, BGStar, and Barozen, among others.
- Sector
- General
- Industry
- Medical - Devices
- Address
- KR
i-SENS, Inc. (099190) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |



